High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4⁺ and CD8⁺ neoantigen-specific T cells to promote antitumor immunity

Abstract

These results indicate that neoantigen-based vaccines are optimized by potentiating IL-2R signaling in CD4⁺ and CD8⁺ neoantigen-reactive T cells by using high-dose mIL-2/CD25, leading to more effective tumor clearance.